Brachytherapy, a form of radiation therapy in which a radiation source is implanted next to the area requiring treatment, is at the core of CivaTech Oncology®, Research Triangle Park, N.C., products. The company’s second low-dose rate (LDR) implantable device, CivaSheet™, has received clearance from the Food and Drug Administration (FDA) for use in treatment of a variety of cancers. The CivaSheet encapsulates LDR palladium in a bioabsorbable polymer-based membrane. The small, flat dots of palladium on the sheet can be custom-fitted to direct the optimal amount of radiation to a specific patient’s cancer—while protecting healthy tissue from collateral damage.
FDA approves low-dose radiation implant
What's New? | December 29, 2014 | By: ATA
You might also like...
New soft robots could self-navigate unknown spaces
Thermal shielding technology for military unveiled
Nextiles Launches AI-powered Intensity Zones
Artificial muscle fibers could serve as cell scaffolds
Exoskeleton helps Parkinson’s patients overcome “gait freeze”
Bio-materials company announces first shipments of commercial Fine Mycelium™